OncoCyte Corporation / Fundamentals
Income statement
- Net revenue
€3.65M - Cost of goods sold
€1.34M - Gross profit
€1.99M - SG&A expenses
€13.00M - R&D expenses
€9.39M - EBITDA
-€53.53M - D&A
€1.25M - EBIT
-€54.73M - Interest expenses
€48.91K - EBT
-€54.41M - Tax expenses
€0.00 - Net income
-€54.41M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€32.69M - Changes in working capital
-€1.27M - Operating cash flow
-€19.77M - Capex
€298.58K - Other investing cash flow
-€519.09K - Net investing cash flow
-€817.67K - Total cash dividends paid
€0.00 - Issuance of common stock
€9.58M - Debt repayment
-€241.96K - Other financing cash flow
€23.51M - Net financing cash flow
€33.48M - Foreign exchange effects
€0.00 - Net change in cash
-€6.32M - Cash at end of period
€22.30M - Free cash flow
-€19.47M
Balance sheet
- Cash and cash equivalents
€20.84M - Cash and short-term investments
€20.84M - Total receivables
€439.30K - Inventory
€594.59K - Other current assets
€1.16M - Total current assets
€23.03M - Property, plant & equipment
€5.73M - Goodwill
€0.00 - Intangible assets
€12.53M - Long-term investments
€0.00 - Other non-current assets
€2.06M - Total non-current assets
€20.31M - Total assets
€43.34M - Accounts payable
€1.10M - Short-term debt
€1.32M - Other current liabilities
€3.29M - Total current liabilities
€5.71M - Long-term debt
€1.57M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€35.12M - Total non-current liabilities
€36.69M - Total liabilities
€42.40M - Common stock
€315.71M - Retained earnings
-€314.85M - Other equity
€72.93K - Total equity
€942.08K - Total liabilities and shareholders' equity
€43.34M
Company information
- Market capitalization
€78.06M - Employees
46 - Enterprise Value
€47.95M
Company ratios
- Gross margin
-
54.5% Much better than peer group: 30.6% - EBITDA margin
-
-1,465.6% Much worse than peer group: -804.5% - EBIT margin
-
-1,498.3% Much worse than peer group: -871.5% - EBT margin
-
-1,489.7% Much worse than peer group: -865.7% - Net margin
-
-1,489.7% Much worse than peer group: -859.6% - ROE
-
-5,775.7% Much worse than peer group: -12.5% - ROA
-
-125.5% Much worse than peer group: -32.1% - Asset turnover
-
8.4% Much worse than peer group: 69.2% - FCF margin
-
-549.4% Much better than peer group: -674.0% - FCF yield
-25.7% - Efficiency ratio
1,565.6% - Net sales per employee
-
€79.40K - Net income per employee
-
-€1.18M